SCHEMBL6797785

SCHEMBL6797785

O=C1NC(=O)C(Cc2ccc(-c3cnc4ccccc4c3)cc2O)N1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 1/20 0.43
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
PRMT5 O14744 1/20 0.41
WDR77 Q9BQA1 1/20 0.41
PIK3CD O00329 1/20 0.40
PIK3CA P42336 1/20 0.40
MAP4K4 O95819 1/20 0.40
CSNK1G2 P78368 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
MAP4K5 Q9Y4K4 1/20 0.40
BIRC5 O15392 1/20 0.38
PDGFRB P09619 1/20 0.38
PDGFRA P16234 1/20 0.38
NR2F2 P24468 1/20 0.38
TOP2A P11388 1/20 0.37
TOP2B Q02880 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18311414 0.71 CA12 (0.55) TDP2CA12CA1CA2CA9
SCHEMBL6842484 0.70 TDP2 (0.45) TDP2CA12CA1CA2CA9
SCHEMBL2869477 0.70 ALDH1A1 (0.45) TDP2MAP4K4CSNK1G2CLK4MKNK2
SCHEMBL6797790 0.70 MAP4K4 (0.46) TDP2CA12CA1CA2CA9
SCHEMBL25677401 0.68 MAP4K4 (0.52) TDP2CA12CA1CA2CA9
SCHEMBL32667946 0.65 PDGFRB (0.77) TDP2CA12CA1CA2CA9
SCHEMBL2772360 0.65 PDGFRB (0.77) TDP2CA12CA1CA2CA9
SCHEMBL8943779 0.65 ADAMTS5 (0.42) PRMT5
SCHEMBL3003119 0.65 ESR2 (0.71) TDP2CA12CA1CA2CA9
SCHEMBL18076579 0.65 TDP2 (0.43) TDP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110809-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110809-A1 Metalloproteinase inhibitors MMP9, MMP2, MMP3 TDP2 2225/4885CA12 245/4885CA1 362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.